Siemens Healthineers Price Target Lowered to EUR 62 From EUR 64 at Barclays
Siemens Healthineers Upgraded to Buy From Neutral at UBS
UBS analyst Graham Doyle upgraded Siemens Healthineers to Buy from Neutral with a price target of EUR 56, down from EUR 59. The company is "finally positioned for a re-rating" with expectations low in
Credit Suisse to hold a conference
2022 London Global Healthcare Conference to be held in London on February 28-March 2.
Smith & Nephew appoints former Siemens Healthineers exec as CEO
Smith & Nephew (NYSE:SNN) appointed Deepak Nath as CEO, effective April 1, succeeding Roland Diggelmann, who will step down by mutual agreement on March 31. Nath joins Smith+Nephew from Siemens
Siemens Healthineers price target lowered to EUR 71.10 at JPMorgan
JPMorgan analyst David Adlington lowered the firm's price target on Siemens Healthineers to EUR 71.10 from EUR 77.50 and keeps an Overweight rating on the shares.
Siemens Healthineers AG Non-GAAP EPS of €0.55, revenue of €5.07B
Siemens Healthineers AG press release (OTCPK:SEMHF): FQ1 Non-GAAP EPS of €0.55.Revenue of €5.07B (+31.3% Y/Y).
Siemens Healthineers Clinitest rapid COVID-19 antigen self-test available in US
Siemens Healthineers (OTCPK:SMMNY) said the Clinitest Rapid COVID-19 Antigen Self-Test1,2 is now available in the U.S. The self-test uses a simple nasal swab to provide accurate COVID-19 test results
Siemens Healthineers launches Enhanced Liver Fibrosis test in US
Siemens Healthineers (OTCPK:SMMNY) launched its Enhanced Liver Fibrosis (ELF) test in the U.S. Currently, the ELF test is exclusively available through collaborations with Labcorp (NYSE:LH) and Quest
Siemens Healthineers reinstated at Buy at Goldman Sachs
Goldman Sachs analyst Veronika Dubajova reinstated coverage of Siemens Healthineers with a Buy rating and a EUR 76 price target. The company is expected to deliver sustainable 6% organic sales growth
Siemens Healthineers upgraded to Buy from Hold at Jefferies
Jefferies analyst James Vane-Tempest upgraded Siemens Healthineers to Buy from Hold with a price target of EUR 75, up from EUR 62. The firm's proprietary Radiation Oncology survey highlighted a compet